Subscribe to RSS
Download PDF
DOI: 10.1160/TH05-05-0342
Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII
Authors
Publication History
Received
17 May 2005
Accepted after resubmission
22 August 2005
Publication Date:
07 December 2017 (online)
Summary
The administration of recombinant activated factor VII (rFVIIa) by continuous infusion has provided a safe and convenient alternative to bolus injections in haemophiliacs with inhibitors, but it has only been reported in a single case with congenital factorVII (FVII) deficiency. The results of 12 consecutive surgical procedures in 7 patients with congenital FVII deficiency are reported here. rFVIIa was always given in continuous infusion, aiming at plasma FVII activity of 0.5 IU/mL. Treatment was given for 2 to 7 days with a mean total dose of 7.8 mg rFVIIa. Blood loss was as expected from the different types of procedures and the only thromboembolic complication was a superficial thrombophlebitis at the infusion site. This mode of substitution was therefore safe, effective and well tolerated.
-
References
- 1 Hedner U, Glazer S, Pingel K. et al Successful use of recombinant factor VIIa in a patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
- 2 Bauer K. Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis 1996; 26 (Suppl. 01) 155-8.
- 3 Ingerslev J, Knudsen L, Hvid I. et al Use of recombinant factor VIIa in factor-VII-deficient patients. Haemophilia 1997; 3: 215-8.
- 4 Jiménez-Yuste V, Villar A, Morado M. et al Continuous infusion of recombinant activated factor VII during caesarian section delivery in a patient withcongenital factor VII deficiency. Haemophilia 2000; 6: 588-90.
- 5 Hedner U. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol 2004; 41 (Suppl. 01) 35-9.
- 6 Wong WY, Huang WC, Miller R. et al Clinical efficacy and recovery levels of recombinant FVIIa (Novo-Seven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia 2000; 6: 50-4.
- 7 White B, O'Connor H, Smith OP. Successful use of recombinant VIIa (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency. Blood Coagul Fibrinolysis 2000; 11: 155-7.
- 8 Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5: 253-9.
- 9 Schulman S, Bech Jensen M, Varon D. et al Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996; 75: 432-6.
- 10 Schulman S. the rFVIIa-CI group. Safety, efficacy and lessons from continuous infusion with rFVIIa. Haemophilia 1998; 4: 564-7.
- 11 Schulman S, Johnsson H, Lindmarker P. Thrombotic complications after substitution with a FVII concentrate. Thromb Haemost 1991; 66: 619 (Letter).
- 12 Mariani G, Herrmann FH, Schulman S. et al International Factor VII Deficiency Study Group. Thrombosis in inherited factor VII deficiency. J Thromb Haemost 2003; 1: 2153-8.
- 13 Mazoyer E, Kevorkian J-P, Biyick E. et al Efficacy and safety of continuous infusion of factor VII concentrate in a factor VII-deficient patient at high risk for arterial thrombosis. Blood Coagul Fibrinolysis 2004; 15: 519-20.
- 14 Eikenboom JC, Bos CF, Briët E. Peri-operative replacement therapy with factor VII concentrate in a patient with severe factor VII deficiency. Thromb Haemost 1992; 67: 285-6.
- 15 Schulman S. Continuous infusion. Haemophilia 2003; 9: 368-75.
- 16 Brummel Ziedins K, Rivard GE, Pouliot RL. et al Factor VIIa replacement therapy in factor VII deficiency. J Thromb Haemost 2004; 2: 1735-44.
- 17 Gershwin ME, Gude JK. Deep vein thrombosis and pulmonary embolism in congenital factor VII deficiency. N Engl J Med 1973; 288: 141-2.
- 18 Nakagawa K, Furusawa A, Momono S. et al Gastrectomy in a patient with congenital factor VII deficiency – a case report. Nippon Ganka Gakkai Zasshi 1990; 91: 771-3.
- 19 Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
- 20 Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.